1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

  • November 2015
  • 262 pages
  • ID: 3606785
In this report:
SALES OF VELCADE WILL SUBSTANTIALLY DECREASE AT A NEGATIVE CAGR OF ##.##%, FROM $##.## BILLION IN 2013 TO $## MILLION IN 2023, DUE TO PATENT EXPIRATION AND THE SHIFT TOWARDS NEWER AND MORE EFFECTIVE THERAPIES.
SALES OF THE CURRENT MARKET LEADER REVLIMID ARE EXPECTED TO DECREASE AT A NEGATIVE CAGR OF ##.##%, FROM $##.## BILLION IN 2013 TO $##.## BILLION IN 2023, WITH SALES PEAKING AT $##.## BILLION IN 2018.

Summary

Table of Contents

Search Inside

PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023

Brief

The Multiple Myeloma market is currently dominated by Velcade and Revlimid, and the sector is set to undergo substantial growth between 2013 and 2023. The principal drivers of growth will be the launch of monoclonal antibodies Empliciti and daratumumab, which will not only provide a additional treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the serious efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the growing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a meaningful expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Features

Key Questions Answered

- The multiple myeloma market is marked by the presence of a number of unmet needs. What are the principal unmet needs in this sector? Will the drugs under development fulfil the unmet needs of multiple myeloma market?

- The late-stage multiple myeloma pipeline has therapies targeting various multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the more significant peak sales at the more important Compound annual growth rate, and why?

- The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of additional mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the main drivers and barriers to this change?

Key Benefits

- The principal driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.

- The second biggest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.

- Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.

- The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.

Overview

- Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and estimate for ten years to 2023.

- Key topics covered include tactical competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.

- Pipeline analysis: exhaustive data split across distinct phases, emerging novel trends under development, and in-depth analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the overall multiple myeloma therapeutics market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

The market research will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop strategic management by understanding the trends shaping and driving the overall multiple myeloma therapeutics market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall multiple myeloma therapeutics market in future.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analysing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Track drug sales in the overall multiple myeloma therapeutics market from 2013-2023.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • January 2018
  • by Infiniti Research Limited

About Gene TherapyOvarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cance ...

Global Cancer Supportive Care Market 2017-2021

Cancer Supportive Care Sector: Worldwide Forecast until 2021

  • $ 3500
  • Industry report
  • September 2017
  • by Infiniti Research Limited

About Cancer Supportive CareCancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cance ...

Kaposi Sarcoma Global Clinical Trials Review, H2, 2017

Clinical Research in Kaposi Sarcoma in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Kaposi Sarcoma Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Kaposi Sarcoma Global Clinical Trials Review, H2, 2017" provides an overview of Kaposi Sarcoma clinical ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.